Erenumab: Uses, Dosage, Side Effects and More

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Subcutaneous
Prophylaxis of migraine

Adult: In patients who have at least 4 migraine days per month: 70 mg once every 4 weeks, may increase to 140 mg every 4 weeks, if necessary. Consider treatment discontinuation if no response after 3 months.

What are the brands available for Erenumab in Malaysia?

Pasurta

Special Precautions

Patient with hypertension or risk factors for hypertension, history of constipation, major CV or cerebrovascular events (e.g. pre-existing MI, stroke, TIA, unstable angina, undergone coronary artery bypass surgery or other revascularisation procedure). Elderly. Pregnancy and lactation.

Adverse Reactions

Significant: Constipation, hypersensitivity reactions (e.g. rash, anaphylaxis, angioedema, swelling/oedema, urticaria), new-onset and worsening of pre-existing hypertension, immunogenicity.
General disorders and administration site conditions: Inj site reactions (e.g. pain, erythema).
Musculoskeletal and connective tissue disorders: Muscle cramps or spasms.
Skin and subcutaneous tissue disorders: Pruritus, rash.

Monitoring Parameters

Monitor blood pressure. Monitor for signs and symptoms of hypersensitivity reactions and severe constipation.

Drug Interactions

May increase the risk of severe constipation and constipation-related complications with drugs associated with reduced gastrointestinal motility.

Action

Description:
Mechanism of Action: Erenumab is a human immunoglobulin G₂ (IgG₂) monoclonal antibody. It binds to and inhibits calcitonin gene-related peptide (CGRP), a peptide involved in migraine pathophysiology.
Pharmacokinetics:
Absorption: Bioavailability: 82%. Time to peak plasma concentration: Approx 6 days.
Metabolism: Metabolised via nonspecific, nonsaturable proteolytic pathway.
Excretion: Elimination half-life: 28 days.

Storage

Store between 2-8°C. Protect from light. If removed from the refrigerator, store up to 30°C and use within 7 days. Do not freeze or shake.

MIMS Class

Antimigraine Preparations

ATC Classification

N02CD01 - erenumab ; Belongs to the class of calcitonin gene-related peptide (CGRP) antagonists preparations. Used to relieve migraine.

References

Aimovig 140 mg Solution for Injection in Pre-filled Pen (Novartis Pharmaceuticals UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 06/11/2024.

Aimovig Injection, Solution (Amgen Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/11/2024.

Anon. Erenumab-aaoe. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 06/11/2024.

Brayfield A, Cadart C (eds). Erenumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/11/2024.

Erenumab. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 06/11/2024.

Joint Formulary Committee. Erenumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/11/2024.

Novartis New Zealand Limited. Aimovig 70 mg/mL, 140 mg/mL Solution for Injection in Pre-filled Pen and Syringe data sheet 6 March 2024. Medsafe. http://www.medsafe.govt.nz. Accessed 06/11/2024.

Pasurta 140 mg/mL Solution for Injection in Prefilled Syringe (Novartis Corporation [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 06/11/2024.

Disclaimer: This information is independently developed by MIMS based on Erenumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com